Deregulated Skp2 function promotes cell transformation, and this is consistent with observations of Skp2 overexpression in many human cancers. However, the mechanisms underlying elevated Skp2 expression are still unknown. Here we show that the serine/ threonine protein kinase Akt1, but not Akt2, directly controls Skp2 stability by a mechanism that involves degradation by the APC-Cdh1 ubiquitin ligase complex. We show further that Akt1 phosphorylates Skp2 at Ser 72, which is required to disrupt the interaction between Cdh1 and Skp2. In addition, we show that Ser 72 is localized within a putative nuclear localization sequence and that phosphorylation of Ser 72 by Akt leads to cytoplasmic translocation of Skp2. This finding expands our knowledge of how specific signalling kinase cascades influence proteolysis governed by APC-Cdh1 complexes, and provides evidence that elevated Akt activity and cytoplasmic Skp2 expression may be causative for cancer progression.
The SCF-Skp2 E3 ubiquitin ligase complex regulates the destruction of numerous cell-cycle regulators including p27, Foxo1 and p130 (ref. 1) . Elevated Skp2 expression is frequently observed in many tumours, including breast and prostate carcinomas 2, 3 . However, the molecular mechanisms underlying elevated Skp2 expression have not been fully explored. We and others have identified Cdh1 as the E3 ligase that promotes Skp2 destruction 4, 5 . Compared with the frequency of Skp2 overexpression, loss of Cdh1 is not a frequent event in human cancer. In contrast, hyperactivation of the Akt pathway is considered a hallmark of many cancers and it has been reported that activation of the phosphatidylinositol-3-OH kinase (PI(3)K)/Akt pathway enhances p27 destruction 6 . This suggests that sustained Akt activity can influence Skp2 activity 7, 8 . The Akt family of kinases includes three closely related family members designated Akt1, Akt2 and Akt3 (ref. 9) . Because most of the upstream regulators and downstream mediators of the Akt pathway are either oncogenes or tumour suppressors, it is not surprising to find that Akt activity is abnormally elevated in most human cancers 10 . Enhanced Akt signalling in tumour cells can suppress apoptosis by promoting the phosphorylation and subsequent cytoplasmic localization of many downstream pro-apoptotic protein targets such as Bad 11 , Foxo1 (ref. 12 ) and Foxo3a 13 . Akt upregulation can also promote cell growth by inactivating the negative cell-cycle regulators p21 (ref. 14) and p27 (refs 15-17) . Most studies exploring a role for the Akt pathway in cell-cycle progression, survival and cancer progression have generally assumed that all three isoforms function in overlapping, redundant roles. However, recent studies have begun to suggest isoform-specific functions for Akt [18] [19] [20] .
Here we have evaluated the mechanism by which Akt controls Skp2 stability and the subcellular localization of Skp2. Our findings provide a mechanistic explanation for elevated Skp2 expression as well as Skp2 cytoplasmic staining in tissues derived from advanced breast and prostate cancers 21, 22 .
ReSulTS

Skp2 expression is regulated by the PI(3)K/Akt pathway
Recent reports have suggested that the PI(3)K/Akt pathway regulates Skp2 expression levels by one or more unknown mechanisms 6, 23 . To investigate the contribution of Akt signalling in Skp2 expression, we first treated HeLa and PC3 cells with the PI(3)K inhibitor LY294002, and found a time-dependent decrease in Skp2 protein levels concomitant with a robust inhibition of PI(3)K activity as revealed by the loss of phospho-Akt (pS473). However, the expression of Cdh1, the known E3 ligase of Skp2, was not affected by LY294002. In addition, the expression of other Cdh1 substrates such as cyclin A did not respond to inhibition of PI(3)K activity ( Fig. 1a; Supplementary Information, Fig. S1a-c) . Second, we used insulin-like growth factor-1 (IGF-1), which potently activates PI(3)K in all cell types, and observed increased Skp2 protein levels also concomitantly with enhanced phosphorylation by Akt ( Supplementary  Information, Fig. S1d, e) . Figure 1b shows that specific depletion of Akt1, but not that of Akt2, markedly decreases Skp2 protein levels in HeLa cells and induces its downstream target p27. However, depletion of Akt1 did not change the expression of Cdh1 and other Cdh1 substrates that we examined (Fig. 1b) . Similar results were also obtained in U2OS cells and SKBR3 cells ( Supplementary Information, Fig. S1f, g ). Conversely, inactivation of PTEN, which results in elevated Akt activity, leads to upregulation of Skp2 in both asynchronized and synchronized HeLa cells (Fig. 1c, d ). This finding is further supported by the positive correlation between Skp2 expression and Akt activity in a panel of breast cancer cell lines (Fig. 1e) . Furthermore, the suppression of Akt activity by LY294002 in both MDA-MB468 and SKBR3 cells leads to downregulation of Skp2 expression, providing further evidence that elevated Akt activity is one major cause of the observed upregulation of Skp2 in these two cell lines ( Supplementary Information, Fig. S1b, c) . Thus, in agreement with previous reports 6, 8 , the PI(3)K pathway regulates Skp2 expression; moreover, this occurs selectively through Akt1 signalling.
Our finding that inactivation of PTEN in mouse embryonic fibroblasts (MEFs) led to mild upregulation (1.5-1.7-fold) of mouse Skp2 levels The PTeN/PI(3)K/Akt pathway regulates both Skp2 transcription and Skp2 stability Next, we examined how Akt regulates Skp2 expression mechanistically. We found that, in agreement with previous reports 24, 25 , inactivation of Akt1, but not that of Akt2, leads to a 40% decrease in Skp2 mRNA levels (Fig. 2a) . This is possibly through either E2F1 or NF-κB pathways that are subjected to regulation by Akt1 (refs 24, 25) . However, we observed a much greater (about eightfold) decrease in Skp2 protein abundance (Fig. 2b) , arguing that Akt1 could also regulate Skp2 expression posttranslationally. To address this possibility further, we assessed the half-life of endogenous Skp2 half-life after modulating the PTEN/Akt pathway. We found that inactivation of Akt1 by short interfering RNA (siRNA) shortened the half-life of endogenous Skp2, whereas depletion of PTEN, in a similar fashion to depletion of Cdh1, stabilized Skp2 ( Fig. 2c, d ; Supplementary Information, Fig. S2 ).
Akt1 interacts with and phosphorylates Skp2 at Ser 72
Sequence analysis revealed that human Skp2 contains an Akt consensus phosphorylation site at Ser 72, which conforms to the optimal Akt motif RxRxxS/T. The motif surrounding Ser 72 is also conserved in Skp2 orthologues in all mammals except mouse (Fig 3a) . We therefore reasoned that Skp2 is a substrate of Akt, whose phosphorylation may influence Skp2 stability. However, because mouse Skp2 lacks the Ser 72 site, it is likely that mouse Skp2 is not an optimal Akt substrate. This explains why a loss of Akt1 would not affect Skp2 expression in MEFs ( Supplementary Information, Fig. S1i ). However, the absence of Ser 72 in Xenopus and zebrafish suggests that the Akt/Skp2 regulatory pathway might be a relatively late event acquired during evolution. Consistent with the hypothesis that Skp2 is a putative Akt substrate, an activated allele of Akt1 (myr-Akt1) interacts with Skp2 as detected by co-immunoprecipitation (Fig. 3b) . Furthermore, when overexpressed in 293T cells, Skp2 specifically interacts with endogenous Akt1 but not Akt2 (Fig. 3c, 3d ). In support of this finding, using both in vivo co-immunoprecipitation (Fig. 3e) and in vitro glutathione S-transferase (GST) pulldown (Fig. 3f) assays, we were able to show that Skp2 interacts specifically with Akt1 but not Akt2. Moreover, we showed that the Skp2 constructs lacking the first 90 amino-acid residues failed to interact with both overexpressed Akt1 (Fig. 3g ) and endogenous Akt1 (Fig. 3h) . These results provide further evidence of the molecular mechanism for the Akt1 isoform-specific regulation of Skp2.
To test whether Skp2 is a substrate for Akt, we first performed in vitro kinase assays. Figure 4a shows that Akt1 phosphorylates wild-type Skp2, but not the S72A mutant. Furthermore, we show that Akt could phosphorylate Skp2 as efficiently as it does another known Akt substrate, Mdm2 (ref. 26) (Supplementary Information, Fig. S3a ). We also examined Skp2 phosphorylation by using a substrate-directed phospho-specific antibody that recognizes the optimal Akt consensus phosphorylation motif 27 ( Fig. 4b) . Because the Scansite program showed that there are additional suboptimal putative Akt phosphorylation sites present in human Skp2, including Thr 21, Ser 75 and Ser 157, to pinpoint the exact Akt phosphorylation site we performed mass spectrometric analysis of GST-WT (wild-type) Skp2 after incubation with myr-Akt. This analysis revealed that Ser 72 is the only phosphorylation event identified under these experimental conditions ( Supplementary Information, Fig. S3b ). Next, we found that expression of activated Akt significantly enhanced the phosphorylation of wild-type Skp2, whereas Skp2-S72A phosphorylation was not detected (Fig. 4c) . The reactivity of Skp2 with the Akt substrate antibody was reversed when the cell lysates were incubated with lambda phosphatase (Fig. 4d) . In addition, Skp2 phosphorylation was detected by the Akt substrate antibody in IGF-1-stimulated cells; moreover, phosphorylation was decreased in cells transduced with Skp2 siRNA or Akt1, but not Akt2, shRNA ( Fig. 4e; Supplementary Information,  Fig. S3f ). Although both Akt1 and Akt2 phosphorylated Skp2 at relatively similar efficiencies in vitro ( Supplementary Information, Fig. S3c ), when overexpressed in 293T cells, Akt1 is more potent than Akt2 in phosphorylating the Skp2 protein ( Supplementary Information, Fig. S3d ). These results are therefore consistent with the notion that endogenous Akt1, but not Akt2, directly phosphorylates Skp2 in cells, and suggests that this may be causally linked to decreased Skp2 expression after Akt1 depletion (Fig. 1b) . It was recently shown that, besides Akt, other AGC-family kinases such as serum and glucocorticoid-inducible kinase (SGK) could also phosphorylate p27, a well-known Akt substrate 28 . We found that Akt is the only kinase capable of phosphorylating Skp2 in vivo: both S6 kinase (S6K) and SGK failed to phosphorylate Skp2 (Fig. 4f) .
High-stringency Akt sites are not found in mouse Skp2, although there are several suboptimal sites, including Thr 21, Ser 75 and Ser 133. This low stringency is consistent with the failure of the phospho-Akt substrate antibody to recognize phosphorylation at any of these sites in mouse Skp2 ( Supplementary Information, Fig. S3e ). Furthermore, we observed only a very weak incorporation of γ-32 P into a mouse GST-Skp2 fusion protein after incubation with myr-Akt in vitro (Fig. 4g) . . Sequence analysis revealed that Ser 75 is a putative casein kinase I (CKI) site. Consistent with this, the CKI ε isoform was found to associate specifically with Skp2 protein by mass spectroscopy (data not shown). This finding was further validated by immunoblot analysis of Skp2 immunoprecipitates (Fig. 5b ). In addition, inhibition of the CKI kinase activity with specific inhibitors resulted in a decrease in Skp2 expression level in both HeLa and U2OS cell lines (Fig. 5c ), indicating that CKI is involved in regulating Skp2 stability by directly phosphorylating the Skp2 protein.
Phosphorylation of the
We reasoned that phosphorylation of Ser 72 might create a priming site that facilitates phosphorylation of Ser 75 by CKI, a mechanism that has been reported for phosphorylation of the Foxo family of transcription factors 30 ( Fig. 5d) . Indeed, we found that replacement of Ser 72 by S4c ). In contrast, mutation of Ser 75 reduced phosphorylation, indicating that CKI-mediated phosphorylation of Skp2 occurs at Ser 75 (Fig. 5f ). These data suggest that CKI may function as the Ser 75 kinase after a priming phosphorylation of Ser 72 by Akt1.
Overexpression of Akt protects Skp2 from Cdh1-mediated destruction
Our previous studies suggested that a region of Skp2 between residues 46 and 90 (refs 4, 5) , which contains both the Akt and CKI phosphorylation sites, is both sufficient and required for interaction with Cdh1. We therefore further examined how Akt and/or CKI phosphorylation affects Non-specific protein co-purified with CKI CKI GST-Skp2 GST
Non-specific protein co-purified with CKI CKI GST-Skp2 GST P-ATP. The kinase reaction products were resolved by SDS-PAGE, and phosphorylation was detected by autoradiography. Full-length blots are provided in Supplementary Information, Fig. S11 .
the interaction between Cdh1 and Skp2. We find that replacement of both Ser 72 and Ser 75 by phospho-mimetic amino acids disrupted the interaction between Skp2 and Cdh1 as detected by both in vitro GST pulldown assays ( Fig. 6a; Supplementary Information, Fig. S4d ) and in vivo co-immunoprecipitation analysis ( Supplementary Information, Fig. S4e ).
In support of this finding, we further demonstrated that overexpression of activated Akt resulted in decreased interaction between Skp2 and Cdh1 in vivo (Fig. 6b) . Next, we asked whether this leads to the stabilization of Skp2. In keeping with previous reports 4, 5 , we found that expression of Cdh1 downregulated wild-type Skp2, whereas overexpression of activated Akt abolished Cdh1-mediated Skp2 destruction. Phospho-mimetic mutants of Ser 72 and Ser 75 (S72D and S75D) were resistant to Cdh1-mediated destruction (Fig. 6c) . Conversely, depletion of endogenous Cdh1 with siRNA upregulated wild-type Skp2 but not the Skp2 S72D/S75D phosphomimetic mutant, further supporting the idea that the S72D/S75D mutant is resistant to Cdh1-mediated destruction (Fig. 6d ). 
Cdh1 activity is required for Akt1-dependent regulation of Skp2 levels
Although Cdh1 is the only E3 ligase identified so far that targets Skp2, Akt1-mediated Skp2 regulation could occur through either Cdh1-dependent or Cdh1-independent mechanisms. To further test the contribution of Cdh1 in Akt-dependent regulation of Skp2, we used siRNA. Figure 6e shows that depletion of Akt1, but not that of Akt2, leads to a decrease in Skp2 protein levels and subsequent accumulation of p27. Conversely, depletion of Cdh1 enhanced upregulation of Skp2 and downregulation of p27. Skp2 levels were restored to normal control levels when both Cdh1 and Akt1 were depleted concomitantly. This result suggests that Cdh1 is required for the ability of Akt1 to regulate Skp2. Thus, in normal cycling cells, the ability of Akt1 to phosphorylate Skp2 at Ser 72 protects Skp2 from Cdh1-mediated degradation, such that loss of Akt1 leads to enhanced Skp2 degradation primarily through the Cdh1-dependent destruction pathway. Also consistent with this was our finding that in T98G cells released from serum starvation, Skp2 expression showed up earlier than most APC-Cdh1 substrates (data not shown) 31, 32 .
Phosphorylation of Skp2 at Ser 72 by Akt affects Skp2 protein stability
Time-course experiments in cells expressing Skp2 mutants and treated with the protein synthesis inhibitor cycloheximide revealed that the effects of Akt on Skp2 protein levels are due to alterations in the halflife of the Skp2 protein (Fig. 7a, b) . To further investigate the effects of Akt1 activity on Skp2 protein levels, various Skp2 constructs were transfected with or without activated myr-Akt and their expression GST proteins:
GST-S75D.Skp2
GST proteins:
GST-Skp2 GST Importin α5
GST-Skp2 GST Importin α7
GST-Skp2 GST levels were monitored during cell-cycle progression. As shown in Fig.  7c, d , wild-type Skp2 protein levels decline rapidly in early G1 when APC-Cdh1 is active, and expression of activated Akt delayed the rate of degradation. The S72A mutant was degraded significantly more rapidly than wild-type Skp2. Conversely, the S72D/S75D mutant was degraded with slower kinetics than wild-type Skp2. Taken together, these data demonstrate that phosphorylation by Akt influences the destruction of Skp2 governed by APC-Cdh1.
As mentioned above, using mass spectrometry we found that in addition to phosphorylation at Ser 72 and Ser 75, the Ser 64 site of Skp2 is phosphorylated in vivo (Fig. 5a) , and the cyclin A-Cdk2 complex was implicated as the kinase responsible 29 . In agreement with a recent report 32 , we found that phosphorylation of Skp2 by cyclin A-Cdk2 at Ser 64 also stabilizes Skp2 ( Supplementary Information, Fig. S5a, b) . However, phosphorylation of Ser 64 did not affect the interaction between Skp2 and Cdh1 in vitro ( Supplementary Information, Fig. S5c ) or in vivo ( Supplementary  Information, Fig. S4e) , indicating that cyclin A-Cdk2 affects Skp2 protein stability through a different mechanism from that of Akt.
Because both cyclin A-Cdk2 and Akt affect Skp2 stability, we next sought to investigate the potential connection between these two kinases. We found that neither overexpression of HA-myr-Akt nor depletion of Akt significantly affects cyclin A or Cdk2 expression levels or their kinase activity ( Supplementary Information, Fig. S6a, b) . In contrast, inactivation of either cyclin A and Cdk2 leads to a significant decrease in Akt activity, as illustrated by the decrease in pS473 Akt signals ( Supplementary Information, Fig. S6c, d ) and the decreased efficiency in phosphorylating Skp2 (Fig. 7e ). This indicates that cyclin A-Cdk2 could execute their function partly through activation of the Akt kinase. However, Akt can efficiently phosphorylate a Skp2 mutant (AAAA.Skp2) that fails to interact with the cyclin A-Cdk2 complex 33 ( Fig. 7f) as well as Skp2 mutants in which Ser 64 is replaced with either Ala or Asp (S64A. Skp2 and S64D.Skp2) (Fig. 7g) . This indicates that phosphorylation of Skp2 by Akt is independent of the phosphorylation event occurring at Ser 64 of Skp2.
Akt phosphorylation of Skp2 promotes its cytoplasmic translocation
Akt has been reported to have a major function in the cellular localization of many of its substrates, including p21, p27 and Foxo1 (refs [14] [15] [16] [17] 34) . Amino-acid alignment of human Skp2 with known Akt substrates revealed that Skp2 also contains a putative nuclear localization sequence (NLS) and that Ser 72 is located within this NLS (Fig. 8a) . Immunofluorescence experiments revealed that the bulk of cellular Skp2 is localized in the nucleus in dividing cells normally. However, a mutant Skp2 whose putative NLS had been deleted (∆NLS.Skp2) was localized predominantly in the cytoplasm ( Fig. 8b; Supplementary Information, Fig. S8a, b) . Previous studies have also indicated that, at least for p21, p27 and Foxo, phosphorylation of serine and/or threonine residues adjacent to the NLS leads to a masking of the NLS mediated by the binding of 14-3-3. Similarly, we and the Pandolfi group (page XXX of this issue) found that the interaction between 14-3-3 and Skp2 was enhanced by activated myr-Akt ( Supplementary  Information, Fig. S7a, b) . Furthermore, we found that the ability to interact with 14-3-3 is greatly decreased in the S72A and ∆NLS Skp2 mutants and that the Skp2 mutant lacking the first 90 amino-acid residues failed to interact with 14-3-3 at all ( Supplementary Information, Fig. S7c, d ). It has been reported previously that phosphorylation of BAD at Ser 136 by Akt promotes its interaction with 14-3-3, disrupting its interaction with Bcl-XL 35 . However, we found that blockage of Akt-induced 14-3-3 interaction with Skp2 by the R18 peptide 36 does not affect the interaction between Skp2 and Cdh1 ( Supplementary Information, Fig. S7e, f) .
There are also documented examples in which phosphorylation of serine or threonine residues near or within the NLS reduces the interaction between the NLS and the importin protein complex, thus affecting nuclear import 37, 38 . Using both immunofluorescence microscopy and cellular fractionation, we found that expression of activated myr-Akt promotes the cytoplasmic localization of wild-type Skp2 ( Fig. 8c; Supplementary  Information, Fig. S7g ). In contrast, the non-phosphorylatable Skp2. S72A mutant is restricted to the nuclear compartment in the presence of activated Akt. Conversely, a significant fraction of the phospho-mimetic Skp2.S72D, Skp2.S72D.S75A and Skp2.S72D.S75D mutants is located in the cytoplasm, and their localization is unaffected by the expression of activated Akt ( Fig. 8c; Supplementary Information, Fig. S9 ). Furthermore, we found that there is a significant pool of cytoplasmic Skp2 in SKBR3 cells, which harbour elevated Akt activity (Fig. 1e) , and that inhibition of Akt activity by LY294002 results in the translocation of Skp2 into the nucleus (Fig. 8d, e) . We found that the Skp2 protein specifically interacts with the nuclear import receptors importin α5 and α7 but not α1, and that phosphorylation of the Ser 72 site by Akt is sufficient to disrupt the interaction between Skp2 and importin α5 and α7 (Fig. 8f-h ). Because the importin complex has a critical function in transporting proteins into the nucleus, we reasoned that the dissociation of Skp2 from the importin complex would retain Skp2 in the cytoplasm. Because the Ser 64 site is very close to the putative NLS, we also investigated the potential effects of Ser 64 phosphorylation on Skp2 cellular localization. In agreement with a previous report 32 , we found that the phosphorylation status of Ser 64 did not affect the cellular localization of Skp2 ( Supplementary Information,  Fig. S8c ). We further demonstrated that whereas phosphorylation of Skp2 by Akt at Ser 72 abolished the interaction between Skp2 and the importin complex, phosphorylation of Ser 64 was not sufficient to disrupt the interaction between Skp2 and the importin complex ( Supplementary  Information, Fig. S10a-c) .
DISCuSSION
The data presented above provide evidence for a novel mechanism by which Akt1-mediated phosphorylation of Skp2 at Ser 72 protects Skp2 from Cdh1-mediated destruction through disruption of the interaction between Skp2 and its E3 ligase Cdh1, as well as by inducing the cytoplasmic translocation of Skp2. The Ser 72 phosphorylation site on human Skp2 is not present in the mouse sequence. Similar inter-species differences have been reported for other Akt substrates, including p27 (ref. 17 ) and caspase-9 (ref. 39). However, the Ser 72 site is conserved in most large mammals (Fig. 3a) . It is plausible that for larger animals with a longer life span than mice, cell-cycle control is more stringent, illustrated by the additional layer of Akt regulation on Skp2 stability.
For most SCF-F-box complexes, the regulation of substrate recognition occurs at the level of the substrate, whereas the interaction of Cdh1 and Cdc20 with their substrates does not usually require any post-translational modifications 40 . Our finding provides another unique mechanism for the selective degradation of Cdh1 downstream targets. This protective mechanism mediated by the Akt pathway is very similar to that of the Cdk2-cyclin E complex, which protects Cdc6 from Cdh1-mediated destruction 41 .
The Akt pathway functions to promote both cell survival and cell growth by inactivating many of its downstream substrates 9 . For p27, p21 and Foxo proteins, phosphorylation by Akt triggers the recruitment of 14-3-3, which results in masking the NLS followed by cytoplasmic translocation 37 . We also observed an enhanced interaction of 14-3-3 with Skp2 in cells expressing activated Akt. Moreover, phosphorylation of Skp2 by Akt at Ser 72 greatly decreases the interaction between Skp2 and importin. It is possible that both of these mechanisms contribute to the cytoplasmic translocation of Skp2 after phosphorylation by Akt 42, 43 . Thus our results offer a molecular mechanism for the cytoplasmic localization of Skp2, which has been observed in many clinical tumour samples and is correlated with aggressive malignancy and poor diagnosis 3, 21, 22, 44 . Our data point to Akt isoform specificity in the regulation of Skp2 protein stability (Fig. 4) . Furthermore, we demonstrated that when overexpressed in 293T cells, human Skp2 interacts specifically with endogenous Akt1 but not with Akt2 (Fig. 3c, d) , although the precise mechanism by which Akt1 can, whereas Akt2 cannot, signal to Skp2 has yet to be defined.
Taken together, our results provide new insight into how Akt activity could influence the Skp2/p27 pathway, which is a known hotspot for mutations in human cancer. On one level, our findings provide a mechanism by which Akt influences cell-cycle progression. On another level, we offer a new mechanism by which Akt affects the order of degradation of specific APC-Cdh1 substrates. Ultimately, these data may provide the rationale for the development of specific Akt1 inhibitors as efficient anti-cancer drugs. 
MeTHODS
Plasmids. Flag-Skp2, HA-Skp2 and HA-myr-Akt1 plasmids were described previously 5, 45 . HA-myr-Akt2 plasmid was purchased from Addgene. The first 90 residues of human Skp2 protein were fused in frame with the GST protein to create the pGEX. WT.human.Skp2 construct. Mouse Skp2 cDNA was amplified from a mouse cDNA library (a gift from Ronald DePinho) with Pfu polymerase (Stratagene). Full-length mouse Skp2 cDNA was subcloned into the pCMV-Flag vector (Sigma) to create the Flag-mouse.Skp2 construct, and the first 90 residues of mouse Skp2 were fused in frame with the GST protein to create the pGEX.WT.mouse.Skp2 construct. Skp2 mutants were generated with the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene). The HA-Cdh1 construct was obtained from Peter Jackson. The HA-S6K. CA and HA-S6K.KD constructs were obtained from John Blenis. The HA-SGK.CA construct was a gift from Suzanne Conzen. The importin α1, importin α5 and importin α7 plasmids were obtained from the DF/HCC DNA Resource Core. were purchased from Invitrogen. Monoclonal anti-Cdh1 (CC43) was purchased from Oncogene. Anti-CKI ε antibody (AP7403a) was purchased from Abgent.
Polyclonal anti-Akt1 isoform-specific antibody was produced in house by immunizing rabbits with a synthetic peptide (VDSERRPHFPQFSYSASGTA). Oligofectamine, Lipofectamine and Plus reagent were purchased from Invitrogen. Recombinant human IGF-1 was purchased from R&D Systems.
siRNAs.
Human Akt1 siRNA oligonucleotide (sense, 5´-GAGUUUGAGUACCUGAAGCUGUU-3´) and human Akt2 siRNA oligonucleotide (sense, 5´-GCGUGGUGAAUACAUCAAGACUU-3´) have been validated previously 20 and were purchased from Dharmacon, or sequences were cloned into the pLKO lentiviral expression system and virus was generated in 293T cells for infection, as described 20 . Mouse Akt1 and mouse Akt2 siRNA oligonucleotides were validated by Laura Benjamin's laboratory (personal communication), and sequences were cloned into the pLKO lentiviral expression system. PTEN-1 (sense, 5´-AGGCACAAGAGGCCCUAGA-3´), PTEN-2 (sense, 5´-AAGAGGAUGGAUUCGACUUAG-3´) and PTEN-3 (sense, 5´-AUCGUUAGCAGAAACAAAAGG-3´) have been validated previously 6, 46 and were purchased from Dharmacon. Luciferase GL2 siRNA oligo was purchased from Dharmacon, and the Cdh1 siRNA oligo has been described previously 5 . Cdk2, cyclin E and cyclin A siRNA oligos have been described previously 47 . As described previously, siRNA oligos were transfected into subconfluent cells with Oligofectamine or Lipofectamine 2000 (Invitrogen) in accordance with the manufacturer's instructions 5, 48 .
Cell culture and cell synchronization. Cell culture, including synchronization and transfection, have been described previously 5 . Where indicated, the PI(3) K inhibitor LY294002 (Sigma) or cycloheximide (Sigma) were added to the cell culture media. INK4a −/− mouse embryonic fibroblasts (MEFs) and INK4a −/− . PTENloxp/loxp MEFs were a gift from Ronald DePinho.
Immunoblots and immunoprecipitation. Cells were lysed in EBC (50 mM Tris-HCl pH 8.0, 120 mM NaCl, 0.5% Nonidet P40) buffer supplemented with protease inhibitors (Complete Mini; Roche) and phosphatase inhibitors (phosphatase inhibitor cocktail set I and II; Calbiochem). The protein concentrations of the lysates were measured with the Bio-Rad protein assay reagent on a Beckman Coulter DU-800 machine. The lysates were then resolved by SDS-PAGE and immunoblotted with the indicated antibodies. For immunoprecipitation, 800 µg of lysates were incubated with the appropriate antibody (1-2 µg) for 3-4 h at 4 °C followed by incubation for 1 h with Protein A-Sepharose beads (GE Healthcare). Immune complexes were washed five times with NETN buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P40) before being resolved by SDS-PAGE and immunoblotted with the indicated antibodies. Quantification of the immunoblot band intensity was performed with ImageJ software.
Skp2 binding assays.
Binding to immobilized GST proteins was performed as described previously 5 . Cellular fractionation. The NE-PER kit (Pierce) was used to perform cellular fractionation in accordance with the manufacturer's instructions. Buffers were supplemented with both protease inhibitor (Roche) and phosphatase inhibitors (Calbiochem).
Real-time RT-PCR analysis.
RNA was extracted with a Qiagen RNeasy mini kit, and the reverse transcription reaction was performed with the ABI Taqman Reverse Transcriptional Reagents (N808-0234). After mixing the resulting template with Skp2 (Hs00180634-m1) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Hs99999905-m1) primers and ABI Taqman Fast Universal PCR Master Mix (4352042), the real-time reverse transcriptase (RT)-PCR reaction was performed with the ABI-7500 Fast Real-time PCR system. Indirect immunofluorescence microscopy. Cells grown on coverslips were fixed in 4% paraformaldehyde and permeabilized with 0.2% Triton X-100. The cells were stained with polyclonal anti-HA antibody (Santa Cruz) and monoclonal anti-Skp2 antibody (Invitrogen) in blocking buffer (3% BSA in PBS) for 30 min, and then rinsed and incubated with secondary Alexa Fluor 594-conjugated anti-mouse antibody and Alexa Fluor 488-conjugated anti-rabbit antibody (Invitrogen) for 1 h. Cells were then rinsed with PBS, stained with 4,6-diamidino-2-phenylindole (DAPI) and mounted. The slides were examined with a fluorescence microscope (Eclipse TE300; Nikon) and digital image analysis software (IPLab; Scanalytics). 
